Is Spravato covered under my pharmacy benefit?

No — under your medical benefit. Because the drug is administered to you at a certified site rather than dispensed to you at a pharmacy, the claim runs through the medical side. This is the most common source of confusion on this treatment: people call about pharmacy coverage, get a copay figure, and are then billed under the medical benefit with coinsurance and a deductible attached.

What exactly should I ask when I call my insurer?

Ask whether esketamine is covered under your medical benefit, what your coinsurance is for it, whether you have met your deductible, what your out-of-pocket maximum is, whether prior authorisation is required and what documentation it needs, and whether the specific treatment site is in network. Use the word "esketamine" as well as "Spravato" — some systems index one and not the other. Write down the date, the reference number, and who you spoke to.

My plan denied it. Does that mean I am not eligible?

Not necessarily, and the two are different questions. Eligibility is a clinical assessment against the FDA label criteria; a denial is a coverage decision that often turns on whether your records document that history in the form the plan wanted. Read the denial letter to see which kind it is — documentation denials are frequently resolved by supplying what was missing.

Can I use a manufacturer copay card with Medicare?

No. The savings programme's own terms exclude people using any state or federal government-funded healthcare programme, naming Medicare, Medicaid, TRICARE, the Department of Defense, and the Veterans Administration. This is a federal restriction rather than a plan decision, so there is nothing to appeal. The separate Johnson & Johnson Patient Assistance Program does not carry that exclusion, so it is worth asking about instead.

Does prior authorisation have to be renewed?

Usually. Plans commonly authorise an initial course and then require reauthorisation to continue, typically with evidence of response. Ask your prescriber's office how long your authorisation runs so a lapse does not interrupt treatment.

Does insurance cover Spravato?

Usually yes, with prior authorisation, and under your medical benefit rather than your pharmacy benefit. That last distinction is where most of the confusion and most of the surprise bills come from.

Last reviewed against the FDA label and SPRAVATO REMS programme materials on July 18, 2026.

The short answer

Most commercial plans and Medicare cover Spravato when the label criteria are documented. Coverage is nearly always conditional on prior authorisation, and the claim runs through your medical benefit because the drug is administered at a certified site rather than dispensed to you.

What prior authorisation asks for is consistent across payers: documented inadequate response to at least two antidepressants, each at an adequate dose for an adequate duration, in the current episode.

If you are denied, the most common reason is that the documentation did not establish that history — not that the plan refuses to cover the drug. That is a fixable problem, and appeals on those grounds are worth pursuing.

Coverage by payer type

Coverage by payer type
Payer	Typically covered?	Prior authorisation?	What you would typically pay	What to watch for
Commercial (employer or marketplace)	Usually, under the medical benefit	Nearly always	Your plan coinsurance on the allowed amount, after any deductible	Whether the certified site is in network, and whether the drug and monitoring generate one claim or two
Medicare Part B	Generally, as an administered drug	Varies; documentation expected either way	20% coinsurance after the $283 annual Part B deductible (2026)	Supplemental (Medigap) coverage can reduce this to near zero. Manufacturer copay cards are not available to you
Medicare Advantage	Usually, but on the plan’s own terms	Nearly always, plan-specific	Plan-specific copay or coinsurance — varies far too much to estimate	Network rules. An out-of-network certified site is the most common cause of a large bill here
Medicaid	Varies by state	Nearly always	Where covered, typically $0 to a few dollars	Your state’s preferred drug list and its step-therapy criteria
VA / TRICARE	Available, via a referral pathway	Referral and authorisation typically required	Service-connected care typically carries no copay	Whether care is in-system or a community-care referral. The pathway is the constraint, not the price
Uninsured	Not applicable	Not applicable	The site’s self-pay rate, which it sets independently	Patient assistance may cover the medication if your income is at or below 300% of the federal poverty level

Commercial (employer or marketplace)
Typically covered?
Usually, under the medical benefit
Prior authorisation?
Nearly always
What you would typically pay
Your plan coinsurance on the allowed amount, after any deductible
What to watch for
Whether the certified site is in network, and whether the drug and monitoring generate one claim or two
Medicare Part B
Typically covered?
Generally, as an administered drug
Prior authorisation?
Varies; documentation expected either way
What you would typically pay
20% coinsurance after the $283 annual Part B deductible (2026)
What to watch for
Supplemental (Medigap) coverage can reduce this to near zero. Manufacturer copay cards are not available to you
Medicare Advantage
Typically covered?
Usually, but on the plan’s own terms
Prior authorisation?
Nearly always, plan-specific
What you would typically pay
Plan-specific copay or coinsurance — varies far too much to estimate
What to watch for
Network rules. An out-of-network certified site is the most common cause of a large bill here
Medicaid
Typically covered?
Varies by state
Prior authorisation?
Nearly always
What you would typically pay
Where covered, typically $0 to a few dollars
What to watch for
Your state’s preferred drug list and its step-therapy criteria
VA / TRICARE
Typically covered?
Available, via a referral pathway
Prior authorisation?
Referral and authorisation typically required
What you would typically pay
Service-connected care typically carries no copay
What to watch for
Whether care is in-system or a community-care referral. The pathway is the constraint, not the price
Uninsured
Typically covered?
Not applicable
Prior authorisation?
Not applicable
What you would typically pay
The site’s self-pay rate, which it sets independently
What to watch for
Patient assistance may cover the medication if your income is at or below 300% of the federal poverty level

Every cell here is a general pattern, not a guarantee about your plan. Confirm with your insurer and the treatment site before scheduling.

What prior authorisation actually requires

Prior authorisation is your insurer approving the treatment before it happens. For Spravato the criteria are unusually consistent between payers, because they track the FDA label.

The core requirement

Documented inadequate response to at least two antidepressant medications — and each of those words is doing work:

Two or more. Some plans want them from different classes.
Inadequate response, meaning the medication was tried and did not sufficiently help. Not stopped after three days, not never collected from the pharmacy.
Adequate dose. A medication left at its starting dose generally does not count.
Adequate duration. Typically six to eight weeks at that adequate dose.
In the current episode. A failed trial from a previous episode years ago usually does not count toward this one.

What your prescriber will need to supply

Generally: your diagnosis, the medication history above with dates and doses, confirmation that the treatment will be given at a REMS-certified site, and often a depression rating scale score establishing current severity. Some plans require step therapy — evidence that specific cheaper options were tried first.

The thing worth doing before the request goes in

Check whether your own record actually supports the criteria. This is the single highest-leverage thing you can do about your own coverage, and almost nobody does it.

Reconstruct your medication history: what you took, roughly when, at what dose, for how long, and why you stopped. Compare it against the list above. If two adequate trials are clearly documented, the request is straightforward. If your history is real but the records are thin — a prescriber who has retired, a pharmacy you no longer use, a period you do not remember well — that is worth surfacing to your prescriber before the request is filed rather than discovering it in a denial letter.

Pharmacy records can often reconstruct more than memory can, and your prescriber's office can usually request them.

If you are denied

A denial is common and is not the end of the process. What matters is understanding what was actually denied.

Read what the denial says

Denials for Spravato usually fall into one of three categories:

Documentation insufficient. The most common. The plan is not saying no to the treatment; it is saying the record did not establish the two-antidepressant history. This is often fixable by supplying what was missing.
Step therapy not satisfied. The plan wants specific alternatives tried first. Sometimes those alternatives have been tried and it was not documented.
Not covered / not medically necessary. The most substantive denial, and the one most likely to need a full appeal.

The internal appeal

Your first route is an appeal to the plan itself. You have a right to one, and to a written explanation of the decision. Your prescriber's office usually leads this, and a peer-to-peer review — your prescriber speaking directly with the plan's reviewing clinician — is often more effective than paperwork alone. Ask whether one is available.

The external review

If the internal appeal fails, you generally have the right to an independent external review by a reviewer not employed by your plan. Their decision is binding on the insurer. HealthCare.gov explains the process and the timelines. (opens in a new tab)

What we are not going to tell you

You will find pages quoting a specific percentage of denials that get overturned on appeal. We could not source such a figure to CMS or to a peer-reviewed publication, so we are not going to put a number on it.

What we can say without inventing anything: a denial on documentation grounds is a different kind of problem from a denial on medical-necessity grounds, and the first is frequently resolved by supplying the missing documentation. That is a description of the process, not a prediction about your case.

Medicaid, and why we will not guess

Medicaid coverage of esketamine is set state by state. Each state runs its own preferred drug list and its own prior-authorisation criteria, and they genuinely differ.

This site does not track all 50 state preferred drug lists. We are telling you that rather than publishing a state-by-state table, because a table we cannot maintain would be worse than no table — it would be wrong in some states and you would have no way to know which.

What holds generally, and is reliable enough to act on:

Where a state Medicaid programme covers esketamine, patient cost is typically $0 to a few dollars.
Prior authorisation is nearly always required, with documented treatment-resistant depression criteria.
The treatment site must be enrolled with your state Medicaid programme, which is a separate question from being REMS-certified.

For your own state, the authoritative source is your state Medicaid programme's own drug list. CMS maintains an index of state Medicaid prescription drug programmes. (opens in a new tab)

Refusing to fabricate state-level detail here is deliberate. It is also the sentence a site trying to farm your click would never write.

Common questions

Is Spravato covered under my pharmacy benefit?: No — under your medical benefit. Because the drug is administered to you at a certified site rather than dispensed to you at a pharmacy, the claim runs through the medical side. This is the most common source of confusion on this treatment: people call about pharmacy coverage, get a copay figure, and are then billed under the medical benefit with coinsurance and a deductible attached.
What exactly should I ask when I call my insurer?: Ask whether esketamine is covered under your medical benefit, what your coinsurance is for it, whether you have met your deductible, what your out-of-pocket maximum is, whether prior authorisation is required and what documentation it needs, and whether the specific treatment site is in network. Use the word "esketamine" as well as "Spravato" — some systems index one and not the other. Write down the date, the reference number, and who you spoke to.
My plan denied it. Does that mean I am not eligible?: Not necessarily, and the two are different questions. Eligibility is a clinical assessment against the FDA label criteria; a denial is a coverage decision that often turns on whether your records document that history in the form the plan wanted. Read the denial letter to see which kind it is — documentation denials are frequently resolved by supplying what was missing.
Can I use a manufacturer copay card with Medicare?: No. The savings programme's own terms exclude people using any state or federal government-funded healthcare programme, naming Medicare, Medicaid, TRICARE, the Department of Defense, and the Veterans Administration. This is a federal restriction rather than a plan decision, so there is nothing to appeal. The separate Johnson & Johnson Patient Assistance Program does not carry that exclusion, so it is worth asking about instead.
Does prior authorisation have to be renewed?: Usually. Plans commonly authorise an initial course and then require reauthorisation to continue, typically with evidence of response. Ask your prescriber's office how long your authorisation runs so a lapse does not interrupt treatment.

Sources

SPRAVATO (esketamine) prescribing information (revised 04/2025) (opens in a new tab) — US Food and Drug Administration
Medicare Part B costs and coinsurance (opens in a new tab) — Centers for Medicare & Medicaid Services
2026 Medicare Parts A & B premiums and deductibles (opens in a new tab) — Centers for Medicare & Medicaid Services
Medicare coverage article: esketamine (SPRAVATO) billing and coding (opens in a new tab) — Centers for Medicare & Medicaid Services
State Medicaid drug programmes and preferred drug lists (opens in a new tab) — Centers for Medicare & Medicaid Services
How to appeal a health plan decision (internal appeal and external review) (opens in a new tab) — HealthCare.gov (US Government)
SPRAVATO withMe Savings Program requirements and terms (opens in a new tab) — Johnson & Johnson Health Care Systems Inc. (manufacturer material)
Johnson & Johnson Patient Assistance Program — quick reference guide (opens in a new tab) — Johnson & Johnson (manufacturer material)
VA mental health services (opens in a new tab) — US Department of Veterans Affairs
988 Suicide & Crisis Lifeline (opens in a new tab) — 988 Suicide & Crisis Lifeline